{"doi":"10.1016/j.carrev.2025.07.012","title":"Outcomes for single antiplatelet, dual antiplatelet, or oral anticoagulation after Amulet: Insights from EMERGE LAA post-approval study","abstract":null,"journal":"Cardiovascular Revascularization Medicine","year":2026,"id":612143,"datarank":0.2905136121547779,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.04909792528966279,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.04909792528966279,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":4,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":337842,"name":"James V. Freeman","orcid":"0000-0002-4614-6879","position":1,"is_corresponding":false},{"id":258311,"name":"Mohamad Alkhouli","orcid":"0000-0003-3847-0959","position":2,"is_corresponding":false},{"id":1576000,"name":"Himanshu Agarwal","orcid":null,"position":3,"is_corresponding":false},{"id":697125,"name":"Megan Coylewright","orcid":"0000-0001-8761-1258","position":4,"is_corresponding":false},{"id":654571,"name":"Akash Makkar","orcid":null,"position":5,"is_corresponding":false},{"id":1351454,"name":"Jordan Anderson","orcid":"0000-0003-1040-1951","position":6,"is_corresponding":false},{"id":866595,"name":"Ryan Gage","orcid":null,"position":7,"is_corresponding":false},{"id":1146826,"name":"Xavier Freixa","orcid":"0000-0002-3203-9060","position":8,"is_corresponding":false},{"id":1576001,"name":"Jens Erik Nielsen-Kudsk","orcid":null,"position":9,"is_corresponding":false},{"id":617696,"name":"Dhanunjaya Lakkireddy","orcid":"0000-0002-1492-2693","position":10,"is_corresponding":false},{"id":1575999,"name":"Atman P. Shah","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Outcomes for single antiplatelet, dual antiplatelet, or oral anticoagulation after Amulet: Insights from EMERGE LAA post-approval study","abstract":"<h4>Background</h4>Outcomes associated with different antithrombotic strategies after Amulet left atrial appendage occlusion (LAAO) are not well described.<h4>Objective</h4>This analysis compared outcomes from patients discharged on dual antiplatelet therapy (DAPT) versus single antiplatelet therapy (SAPT) or oral anticoagulation (OAC) following Amulet implant in the EMERGE LAA post-approval study.<h4>Methods</h4>Patients with a successful Amulet implant and discharged from the hospital between August 14, 2021 and December 15, 2023 and entered into the National Cardiovascular Data Registry (NCDR) LAAO Registry were included. A safety endpoint of all-cause death, stroke, major bleeding, or systemic embolism and effectiveness endpoint of ischemic stroke, systemic embolism, or cardiovascular death were assessed through 6 months as well as major adverse events.<h4>Results</h4>A total of 11,445 patients were included in this analysis with 9355 discharged on DAPT (81.7 %), 606 on SAPT (5.3 %), and 1484 on OAC (13.0 %). Patients in the SAPT group had more comorbid conditions and were at the greatest bleeding risk pre-Amulet implant. At 45-days, clinically relevant closure (≤3 mm peri-device leak) was achieved in >95 % of all patients. At 6 months, the safety endpoint rates were 8.8 %, 7.0 %, and 7.0 % in the DAPT, SAPT, and OAC groups, respectively (p = 0.045) and effectiveness endpoint rates were 2.1 %, 1.6 %, and 1.7 % in the DAPT, SAPT, and OAC groups, respectively (p = 0.511). Despite higher baseline bleeding risk, the SAPT group had numerically lower bleeding rates than the DAPT group through 6 months (DAPT 4.8 % vs. SAPT 3.9 %; HR 1.23 [0.78, 1.95]) with no difference in device-related thrombus rates (DAPT 0.8 % vs. 0.8 % SAPT; HR 0.91 [0.33, 2.50]). However, after adjusting for differences in baseline characteristics, no significant differences (p > 0.05) were noted for any clinical events between the three medication groups at 45 days or 6 months.<h4>Conclusion</h4>In the present cohort of patients treated with Amulet LAAO there were high rates of LAA complete closure, and SAPT emerged as a viable alternative to the current DAPT regimen potentially reducing the risk of bleeding complications in patients at high risk without compromising effectiveness.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40750556","pmcid":null,"openalex_id":null,"authors":[],"funders":[{"funder_name":"Abbott Pharmaceuticals","grant_id":"","title":null}],"total_grants":1,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":null,"license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1553838925003987?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1553838925003987?httpAccept=text/plain","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":["Atrial Appendage","Humans","Atrial Fibrillation","Hemorrhage","Anticoagulants","Platelet Aggregation Inhibitors","Treatment Outcome","Administration, Oral","Registries","Risk Assessment","Risk Factors","Retrospective Studies","Product Surveillance, Postmarketing","Time Factors","Aged","Aged, 80 and over","Middle Aged","Female","Male","Septal Occluder Device","Dual Anti-Platelet Therapy","Ischemic Stroke"],"keywords":["Atrial fibrillation","Left Atrial Appendage","Antithrombotic Medication","Amulet","Laao Registry"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T01:46:19.199281Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}